Address: Rue de Stallestraat 63/4, B-1180 Brussels,Belgium
Tel:
Web: http://www.octapharma.com/en.html
Our Group-wide mission is the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our Mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins. We respect human plasma as a sparce resource for life saving therapies.
The Octapharma portfolio focuses on protein and other biopharmaceutical products derived from human plasma, in three therapeutic areas:
Haematology
Coagulation factors to treat bleeding disorders.
Intensive Care and Emergency Medicine
Plasma and blood proteins (such as albumin) used to stabilise blood circulation, restore coagulation function, and prevent shock, e.g., for heavy burns, injuries, and in surgery.
Immunotherapy
Immunoglobulins to treat immune disorders and prevent rhesus incompatibility in pregnancies.
During the COVID-19 pandemic and the multi-stakeholder collaboration needed to find solutions, AstraZeneca launched the Partnership for Health System Sustainability and Resilience (PHSSR) in collaboration with KPMG, the London School…
Erik Present outlines Healixia’s progress in the past three years as the association which brings together medical professionals from across the Belgian healthcare and life sciences ecosystem has grown. Present…
PharmaScan BeLux is a non-profit organization established by pharma.be and Medaxes with the objective to collect and share reliable data on medicines delivered by pharmaceutical companies and distributors to healthcare…
Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its…
Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million…
One year into his first country management assignment at Takeda Belgium, Michael Nesrallah reflects on his initial impressions of the Belgian pharma market as well as its similarities and differences…
Alexander Natz of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) casts his eye over the potential effects of the upcoming EU Pharmaceutical Legislation for small- and medium-sized enterprises in Europe.…
After a 25-year-long career at Roche, spent at local affiliates in Switzerland, Germany, and the Netherlands, as well as in global positions in Switzerland and the US, Marie-José Borst took…
With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that…
Belgium’s drug reimbursement system has become increasingly lengthy and complex, compromising patient access to innovative medicines. The roadmap recently presented by the Minister of Health and the Belgian National Institute…
A roundup of some of the biggest pharma news from Belgium including Neuraxpharm’s new Belgian affiliate, Novalis Biotech’s investment in Rarity Bioscience, Catalent’s plasmid DNA manufacturing site and a recent…
Edward Mc Gettrick and Sharon Gorman of Pfizer, writing in the January 2023 edition of DIA’s Global Forum magazine, examine the scope and impact of the European Union’s new Regulation on…
See our Cookie Privacy Policy Here
